Mesa Laboratories appoints Mark Capone to Board of Directors

MESA LABORATORIES INC /CO/

Board expanded from 6 to 7 members; Capone appointed effective Jan 5, 2024.
Capone most recently served as CEO/President of Myriad Genetics; also 17 yrs at Eli Lilly.
Appointed to Audit Committee, replacing Shiraz Ladiwala.
Capone determined independent under Nasdaq and SEC rules.
No related party transactions with Mesa reported.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Capone

Director

MLAB · MESA LABORATORIES INC /CO/

Effective: 2024-01-05
Filed: January 8, 2024, 6:59 PM ET

Effective January 5, 2024, the Board of Directors (“Board”) of Mesa Laboratories, Inc. (“Mesa ”), upon the recommendation of its Nominating and Governance Committee, voted to expand the size of the Board from six to seven members, and to appoint Mark Capone to fill the newly created seat.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark Capone was appointed as Director at MESA LABORATORIES INC /CO/.

Action: appointed
Role: Director

Exact text from the filing

Effective January 5, 2024, the Board of Directors (“Board”) of Mesa Laboratories, Inc. (“Mesa ”), upon the recommendation of its Nominating and Governance Committee, voted to expand the size of the Board from six to seven members, and to appoint Mark Capone to fill the newly created seat.

View on SEC.gov

MESA LABORATORIES INC /CO/ filing history →

Source: SEC EDGAR

accession 0001437749-24-000821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.